Humasis Co

Humasis Co Revenue per Share

The Revenue per Share of Humasis Co (205470.KQ) as of Nov 9, 2026 is 945.12 KRW. In the previous year, Revenue per Share was 797.62 KRW — a change of 18.49% (higher).

Revenue per Share

945.12KRW

YoY

18.49%

Last updated:

Revenue per Share of Humasis Co is 2025 945.12 KRW. Revenue per Share of Humasis Co was 2024 797.62 KRW. It decreases by 18.49% higher compared to the previous year.

The Humasis Co Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2018
303.12 KRW
Jan 1, 2019
287.20 KRW
Jan 1, 2020
1,434.87 KRW
Jan 1, 2021
10,100.85 KRW
Jan 1, 2022
14,791.25 KRW
Jan 1, 2023
433.98 KRW
Jan 1, 2024
797.62 KRW
Jan 1, 2025
945.12 KRW
The Humasis Co Revenue per Share history
YEARRevenue per ShareYoY
945.12KRW+18.49%
797.62KRW+83.79%
433.98KRW-97.07%
14,791.25KRW+46.44%
10,100.85KRW+603.96%
1,434.87KRW+399.61%
287.20KRW-5.25%
303.12KRW+13.51%
267.04KRW—
0.00KRW—
0.00KRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Revenue per Share of Humasis Co is 945.12 KRW in 2025.

Revenue per Share of Humasis Co changed from 797.62 KRW to 945.12 KRW, representing a 18.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Humasis Co

All Key Metrics — Humasis Co